Aptose Biosciences Inc To Hold KOL Event And Corporate Update Call Transcript

Jun 02, 2022 / 08:30PM GMT
Operator

Good afternoon, and welcome to the Aptose Biosciences KOL data call. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Aptose website following the conclusion of the event.

I'd now like to turn the call over to Dr. William Rice, President and Chief Executive Officer of Aptose Biosciences. Please go ahead, William.

William G. Rice - Aptose Biosciences Inc. - Chairman, President, CEO & CAO

Thank you, Tera. Good day all, and thank you for joining us. I am Dr. William Rice, Chairman, President and CEO of Aptose Biosciences. Aptose is a clinical stage biotech company, developing oral kinase inhibitors for the treatment of patients with hematologic malignancies. And today, we'll hold an AML-focused KOL event and a high-level update on our clinical programs. And as a reminder, we will make certain forward-looking statements today.

At Aptose, we're developing 2 distinct clinical-stage oral kinase inhibitors. Our most advanced molecule, HM43239 or just 239 as we call it, is a clinically

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot